FDA Issues Warning Letter to Amazon for Unapproved Drug Products
FDA issued a warning letter to Amazon.com, Inc. after purchasing and reviewing products sold through Amazon’s website and fulfilled through Amazon’s logistics network. The products identified were “Vajraang Phimosis Mini Combo,” “Penile Heal Cream,” and “Beilloso Balanitis Relief Cream.”
FDA determined the products were unapproved new drugs because their labeling included claims related to phimosis, paraphimosis, and balanitis. FDA noted that these claims indicated the products were intended for diagnosis, cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body.
The letter is particularly significant because FDA emphasized that the products were introduced or delivered for introduction into interstate commerce through Amazon’s Fulfillment by Amazon service. FDA directed Amazon to respond within 15 business days with corrective actions and preventive measures.
MDP Perspective
This warning letter should get the attention of online marketplaces, fulfillment providers, and third-party sellers.
FDA is not only looking at product manufacturers. It is also scrutinizing distribution channels when unapproved drug products reach U.S. consumers through major online platforms.
The Amazon letter reinforces that e-commerce companies need stronger controls over health-related claims, product listings, fulfillment pathways, and third-party seller compliance. Marketplace scale does not eliminate regulatory responsibility.
Links
Warning letter to Leading Edge Health, Inc.
Warning Letter to Wild Arabic Herbs
FDA Issues 14 Warning Letters Targeting Online Unapproved Drug Sales
FDA Approves Retevmo for RET Fusion-Positive Solid Tumors
FDA Grants Full Approval to Retevmo for RET Fusion-Positive Metastatic Solid TumorsApproval expands precision medicine option for adults and children with advanced cancers The U.S. Food and Drug Administration (FDA) has granted traditional approval to Retevmo...
FDA Warning Letters Target Online Ketamine Sellers
Seven Warning Letters Signal Increased FDA Scrutiny The U.S. Food and Drug Administration (FDA) has launched a coordinated enforcement action against websites marketing unapproved ketamine-related drug products, issuing seven Warning Letters on July 7, 2026, to online...
FDA Warns Wild Arabic Herbs Over Product Cancer Claims
FDA Warns Wild Arabic Herbs Over Cancer Claims for Herbal Product FDA issued a warning letter to Wild Arabic Herbs after reviewing the company’s website and determining that its “Edral-17t” product was marketed as an unapproved new drug. FDA cited claims that the...
FDA Warns Leading Edge Health Over Unapproved New Drugs
FDA Warning Letter Targets Erectin Stimulating Gel and VigRX Delay Wipes FDA issued a warning letter to Leading Edge Health Inc. after reviewing the company’s website and determining that two sexual health products were being marketed as unapproved new drugs. The...
FDA Targets Online Marketing of Unapproved Drugs
FDA Issues 14 Warning Letters Targeting Online Unapproved Drug Sales The U.S. Food and Drug Administration (FDA) has issued a coordinated series of warning letters targeting companies marketing unapproved drug products online, signaling an intensified enforcement...
FDA Approves First Treatment to Reduce Risk of Acute Pancreatitis
FDA Approves First Treatment Proven to Reduce Acute Pancreatitis Risk in Severe HypertriglyceridemiaAn important example of the distinction between surrogate endpoints and clinical outcomes in drug development The U.S. Food and Drug Administration (FDA) has approved...
